Owusu-Agyemang Pascal, Soliz Jose, Hayes-Jordan Andrea, Harun Nusrat, Gottumukkala Vijaya
Department of Anesthesiology and Perioperative Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA,
Ann Surg Oncol. 2014 May;21(5):1487-93. doi: 10.1245/s10434-013-3221-1. Epub 2013 Aug 28.
The perioperative coagulopathy, hemodynamic instability, and infectious complications that may occur during cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) has raised concerns about the safety of epidural analgesia in patients undergoing such procedures.
We conducted a retrospective review of the perioperative anesthetic management of 215 adult patients who had undergone CRS with HIPEC with epidural analgesia. We reviewed epidural-related complications and analyzed the effect of early initiation of continuous epidural analgesia on estimated blood loss, intraoperative fluid administration, blood transfusion and vasopressor requirements, time to extubation, and length of stay.
No epidural hematomas or abscesses were reported. Two patients (0.9 %) had delays in epidural removal because of thrombocytopenia, and two had epidural-site erythema (0.9 %). The majority of postoperative epidural-related hypotensive episodes were successfully treated with fluid boluses. Early initiation of epidural analgesic infusions (before HIPEC) was associated with significantly less surgical blood loss and fluid requirements (P = 0.005 and 0.02, respectively). Pre-HIPEC initiation of epidural infusions was not associated with a statistically significant difference in the following: volume of blood transfused, intraoperative vasopressors use, time to extubation, and length of hospital stay.
With close hematologic monitoring and particular attention to sterility, epidural analgesia can be safely provided to patients undergoing CRS with HIPEC. Early initiation of continuous epidural infusions during surgery could lead to decreased blood loss and less intraoperative fluid administration. Prospective randomized studies are required to further investigate these potential benefits.
在减瘤手术(CRS)联合热灌注腹腔化疗(HIPEC)过程中可能发生的围手术期凝血功能障碍、血流动力学不稳定及感染性并发症引发了对接受此类手术患者实施硬膜外镇痛安全性的担忧。
我们对215例接受CRS联合HIPEC并采用硬膜外镇痛的成年患者的围手术期麻醉管理进行了回顾性研究。我们回顾了硬膜外相关并发症,并分析了早期开始持续硬膜外镇痛对估计失血量、术中液体输注、输血及血管升压药需求、拔管时间和住院时间的影响。
未报告硬膜外血肿或脓肿。两名患者(0.9%)因血小板减少导致硬膜外导管拔除延迟,两名患者出现硬膜外部位红斑(0.9%)。大多数术后硬膜外相关低血压发作通过快速补液成功治疗。早期开始硬膜外镇痛输注(在HIPEC之前)与手术失血量和液体需求量显著减少相关(分别为P = 0.005和0.02)。在以下方面,HIPEC前开始硬膜外输注未显示出统计学上的显著差异:输血量、术中血管升压药使用、拔管时间和住院时间。
通过密切的血液学监测并特别注意无菌操作,可为接受CRS联合HIPEC的患者安全提供硬膜外镇痛。术中早期开始持续硬膜外输注可减少失血量并减少术中液体输注量。需要进行前瞻性随机研究以进一步探究这些潜在益处。